Maria Grazia D'Errigo Selected Research

Lenalidomide (CC 5013)

12/2015	Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
11/2013	Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.
9/2010	Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maria Grazia D'Errigo Research Topics

Disease

5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2023 - 09/2010
2	Thrombocytopenia (Thrombopenia) 10/2023 - 03/2017
2	Disease Progression 10/2023 - 03/2017
2	Hemorrhage 10/2023 - 03/2017
2	Anemia 12/2015 - 11/2013
1	Chromosome Aberrations (Chromosome Abnormalities) 09/2010
1	Chromosome 5q Deletion Syndrome 09/2010

Drug/Important Bio-Agent (IBA)

3	Lenalidomide (CC 5013)FDA Link 12/2015 - 09/2010
2	eltrombopag FDA Link 10/2023 - 03/2017
1	Thrombopoietin ReceptorsIBA 03/2017
1	ribosomal protein S14IBA 09/2010